Antisense Oligonucleotide-mediated Suppression of Muscle Glycogen Synthase 1 Synthesis as an Approach for Substrate Reduction Therapy of Pompe Disease-Reference-Cited by-同舟云学术

Antisense Oligonucleotide-mediated Suppression of Muscle Glycogen Synthase 1 Synthesis as an Approach for Substrate Reduction Therapy of Pompe Disease

Published:2014-01 Issue: Volume:3 Page:e206
ISSN:2162-2531
Container-title:Molecular Therapy - Nucleic Acids
language:en
Short-container-title:Molecular Therapy - Nucleic Acids

Author:

Clayton Nicholas P,Nelson Carol A,Weeden Timothy,Taylor Kristin M,Moreland Rodney J,Scheule Ronald K,Phillips Lucy,Leger Andrew J,Cheng Seng H,Wentworth Bruce M

Publisher

Elsevier BV

Subject

Drug Discovery,Molecular Medicine

Reference33 articles.

1. Pompe's disease;van der Ploeg;Lancet,2008

2. Myozyme Presecribing Infromation www.myozyme.com

3. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial;Amalfitano;Genet Med,2001

4. Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapy;Winkel;Muscle Nerve,2003

5. Enzyme replacement therapy in classical infantile pompe disease: results of a ten-month follow-up study;Klinge;Neuropediatrics,2005

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systematic Review of Genetic Substrate Reduction Therapy in Lysosomal Storage Diseases: Opportunities, Challenges and Delivery Systems;BioDrugs;2024-08-23

2. Advances in Pompe Disease Treatment: From Enzyme Replacement to Gene Therapy;Molecular Diagnosis & Therapy;2024-08-12

3. Skeletal muscle effects of antisense oligonucleotides targeting glycogen synthase 1 in a mouse model of Pompe disease;2024-02-22

4. Risk of Cardiac Arrhythmias in Patients with Late-Onset Pompe Disease—Results from a Long Follow-Up in a Group of 12 Patients and Review of Literature;Cardiogenetics;2024-02-12

5. Advances in functional lipid nanoparticles: from drug delivery platforms to clinical applications;3 Biotech;2024-01-29